Physician profile
Michael G Tedla
NPI 1689061657
$21,844.96
in general payments reported to CMS, 2019-2025
30 companies · $3,480 in 2025
The $3,480 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,032 · 2020: $179 · 2021: $3,452 · 2022: $4,479 · 2023: $5,281 · 2024: $3,942 · 2025: $3,480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Travel and Lodging: $2,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,029.91 |
| Travel and Lodging | $2,672.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,011.75 | 2021-2025 | Micra, Abre, Hawkone |
| Inari Medical, INC. | $2,578.44 | 2021-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Penumbra, INC. | $2,166.85 | 2022-2025 | Indigo System, Ruby Coil, Penumbra System |
| Abbott Laboratories | $2,154.45 | 2019-2025 | Perclose Prostyle, Mitraclip, Supera |
| Boston Scientific Corporation | $2,094.46 | 2019-2025 | Eluvia, Enroute Transcarotid Neuroprotection System, Resonate El Icd Vr |
| Edwards Lifesciences Corporation | $1,628.64 | 2021-2025 | Konect Resilia, Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| W. L. Gore & Associates, INC. | $1,556.51 | 2022-2025 | Excluder Conformable Aaa Endoprosthesis With Active Control, Gore Tag Thoracic Branch Endoprosthesis, Gore Tag Thoracic Endoprosthesis |
| Cardiovascular Systems INC. | $760.47 | 2021-2023 | Diamondback Coronary |
| Stryker Corporation | $598.88 | 2025 | Flowtriever, Inthrill Thrombectomy Catheter, Ct Thrombectomy System Kit |
| Shockwave Medical, INC | $545.87 | 2022-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Biotronik INC. | $474.57 | 2022-2025 | Amvia Edge, Acticor 7 Vr-T Dx, Biomonitor |
| Philips North America LLC | $307.93 | 2023-2025 | Intracardiac Undivided, Labosys, (Az7) Lasers |
| Novartis Pharmaceuticals Corporation | $250.08 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $249.96 | 2019-2024 | Farxiga |
| Angiodynamics, INC. | $244.40 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cordis US Corp. | $224.01 | 2022-2024 | Precise Pro Rx |
| Cardiva Medical, INC. | $134.52 | 2023-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs, Savvywire |
| Janssen Pharmaceuticals, INC | $125.00 | 2019 | |
| Abiomed | $120.91 | 2023 | Impella |
| Janssen Scientific Affairs, LLC | $98.91 | 2020 | |
| Ekos Corporation | $96.50 | 2019 | |
| Terumo Medical Corporation | $89.53 | 2022-2023 | Angio-Seal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.04 | 2023-2024 | Jardiance |
| Amgen INC. | $58.67 | 2020-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $56.52 | 2022-2025 | Lifevest |
| Cvrx, INC. | $44.57 | 2023 | Barostim Neo System |
| Endologix LLC | $29.11 | 2022 | |
| Lantheus Medical Imaging, INC. | $28.97 | 2022 | |
| Kestra Medical Technology Services, INC. | $27.71 | 2023 | Assure Wcd |
| Reflow Medical INC | $17.73 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tedla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.